Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509193 | 0.79 | HTR6 (0.42) | CA2MAPTTDP1CA12CA9 | |
| SCHEMBL15486107 | 0.76 | PSIP1 (0.52) | CA2F2MAPTCA12CA9 | |
| SCHEMBL29948431 | 0.74 | ALDH1A1 (0.35) | CA2PLCG1F2PRSS1PRSS2 | |
| SCHEMBL116525 | 0.74 | LMNA (0.59) | CA2PLCG1MAPTMMP2CA12 | |
| SCHEMBL17493444 | 0.73 | F2 (0.36) | CA2PLCG1F2PRSS1PRSS2 | |
| SCHEMBL15576009 | 0.72 | CA2 (0.48) | CA2PLCG1F2PRSS1PRSS2 | |
| SCHEMBL20613220 | 0.71 | CA2 (0.46) | CA2PLCG1F2PRSS1PRSS2 | |
| SCHEMBL7301352 | 0.70 | F2 (0.55) | CA2PLCG1F2PRSS1PRSS2 | |
| SCHEMBL17548189 | 0.69 | PLCG1 (0.48) | CA2PLCG1F2PRSS1PRSS2 | |
| SCHEMBL17493440 | 0.68 | CA2 (0.44) | CA2PLCG1F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180338-B1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INT (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-3180338-A1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | Boehringer Ingelheim International GmbH (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-9422312-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422312-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422312-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| WO-2016023789-A1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023789-A1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039846-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039846-A1 | AZABENZIMIDAZOLE DERIVATIVES | PRKAB1, PRKAB2, PRKAG1 | CA2 2650/4885PLCG1 3311/4885F2 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.